HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CGP 37157

benzothiazepine derivative of clonazepam; inhibits the in vitro activity of mitochondrial sodium-calcium exchange

Also Known As:

CGP-37157

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Kapelios, Chris: 1 article (07/2018)
2.	Malliaras, Konstantinos: 1 article (07/2018)
3.	Manolis, Antonis S: 1 article (07/2018)
4.	Nanas, Ioannis: 1 article (07/2018)
5.	Nanas, John N: 1 article (07/2018)
6.	Papalois, Apostolos: 1 article (07/2018)
7.	Sfakianaki, Titika: 1 article (07/2018)
8.	Sousonis, Vasilios: 1 article (07/2018)
9.	Sventzouri, Stefania: 1 article (07/2018)
10.	Vakrou, Styliani: 1 article (07/2018)

Related Diseases

1.	Ischemia 07/01/2018 - "Animals were randomized to receive intracoronary infusion of 0.02 mg/kg CGP-37157 or vehicle, either before ischemia (n=17) or before reperfusion (n=17). " 03/15/2002 - "Application of CGP-37157 significantly inhibited effluxes of all FFAs during both ischemia and reperfusion. " 07/01/2018 - "We examined the effects of CGP-37157, a selective mNCX inhibitor, on arrhythmogenesis, infarct size (IS), and no reflow area (NRA) in a porcine model of ischemia-reperfusion. " 07/01/2018 - "Administration of CGP-37157 before ischemia resulted in the following: (a) suppression of ventricular tachyarrhythmias (events/pig: 1.5±1.1 vs 3.5±1.9, p=0.014), (b) easier cardioversion of ventricular tachyarrhythmias (defibrillations required for cardioversion of each episode: 2.6±2.3 vs 6.2±2.1, p=0.006), and (c) decreased maximal depression of the J point (0.75±0.27 mm vs 1.75±0.82 mm, p=0.007), compared to controls. "
2.	Ventricular Tachycardia 07/01/2018 - "Administration of CGP-37157 before ischemia resulted in the following: (a) suppression of ventricular tachyarrhythmias (events/pig: 1.5±1.1 vs 3.5±1.9, p=0.014), (b) easier cardioversion of ventricular tachyarrhythmias (defibrillations required for cardioversion of each episode: 2.6±2.3 vs 6.2±2.1, p=0.006), and (c) decreased maximal depression of the J point (0.75±0.27 mm vs 1.75±0.82 mm, p=0.007), compared to controls. "
3.	Myocardial Infarction 07/01/2018 - "In a porcine model of myocardial infarction, intracoronary administration of CGP-37157 did not decrease IS or NRA. "
4.	Infarction (Infarctions) 07/01/2018 - "We examined the effects of CGP-37157, a selective mNCX inhibitor, on arrhythmogenesis, infarct size (IS), and no reflow area (NRA) in a porcine model of ischemia-reperfusion. "
5.	Hypertrophy 01/01/2018 - "To explore the consequences of mitochondrial Ca2+ accumulation, we tested the effects of kaempferol, an activator of mitochondrial Ca2+ uniporter (MCU), CGP-37157, an inhibitor of mitochondrial Na+/Ca2+ exchanger, and MCU inhibitor Ru360 in rat ventricular myocytes (VMs) from control rats and rats with hypertrophy induced by thoracic aortic banding (TAB). "

Related Drugs and Biologics

1.	NAD (NADH)
2.	Ru 360
3.	kaempferol

Related Therapies and Procedures

1.	Electric Countershock (Cardioversion)